De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer

Prior treatment

• Prior radiation to the pelvis.
• Currently receiving any investigational agents.

Other illness

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inflammatory bowel disease, or irritable bowel disease.

Lab values

• Patients with HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.

• Histologically or cytologically confirmed stage IIIA-IVA endometrial cancer, or any stage I-IVA where any proportion of the tumor is uterine serous, clear cell, de-differentiated, or carcinosarcoma histology.
• Must have already undergone radical hysterectomy. Hysterectomy may have occurred no more than one year prior to enrollment.
• At least 18 years of age.
• ECOG performance status ≤ 2
• Minimal bone marrow and organ function as defined below:
  • Leukocytes ≥ 1,000 cumm
  • Absolute neutrophil count ≥ 500 cumm
  • Platelets ≥ 50,000 cumm
  • Hemoglobin ≥ 7g/dL
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).